KCM
ALXN

Kingdon Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Kingdon Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-135,500
Closed -$15.2M – 73
2020
Q2 		$15.2M Buy
135,500
+20,500
+18% +$2.18M 1.38% 22
2020
Q1 		$10.3M Buy
+115,000
New +$11.3M 1.89% 23
2017
Q1 		– Sell
-45,000
Closed -$5.51M – 154
2016
Q4 		$5.51M Buy
+45,000
New +$5.51M 0.27% 90

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kingdon Capital Management's ALXN Position: Q3 2020 in Review

Kingdon Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2020, closing a stake of 135,500 shares — an estimated $15.2M sold.

Kingdon Capital Management first reported a position in ALXN in Q4 2016 and held it in 3 quarters. The position peaked at $15.2M in Q2 2020. 709 funds tracked by Wall St. Rank hold ALXN as of Q3 2020.

  • Kingdon Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Kingdon Capital Management sold 135,500 Alexion Pharmaceuticals shares in Q3 2020, an estimated $15.2M.
  • Kingdon Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Kingdon Capital Management's Alexion Pharmaceuticals position peaked at $15.2M in Q2 2020.
  • 709 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2020.

Based on Kingdon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.